JPRN-jRCT2080223724已完成2 期
K-163-SZ Phase2 placebo-controlled study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •(1) Patients diagnosed with schizophrenia based on the diagnostic criteria of DSM-5.
- •(2) Patients give their own written informed consent.
排除标准
- •(1) Patients with mental disorders other than schizophrenia or patients with amnestic disorders such as dementia.
- •(2) Patients with a history of organic disorders of the brain.
- •(3) Patients with serious gastrointestinal disorders, respiratory disorders, nervous system disorders, hematologic disorders, endocrine disorders, immune disorders or other systemic disorders.
研究者
相似试验
未知
2 期
K012 phase II clinical studyColorectal cancerJPRN-jRCT2080220752ippon Kayaku Co., Ltd.
进行中（未招募）
不适用
A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic cancer - metformin and pancreatic cancerlocally advanced and metastatic pancreatic cancerMedDRA version: lltLevel: LLTClassification code 10033604Term: <Manually entered code. Term in E.1.1>EUCTR2009-017716-32-NLAcademic Medical Center
已完成
2 期
A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic cancermetastatic pancreatic cancer10017991NL-OMON34831Academisch Medisch Centrum120
已完成
2 期
Statins in Sepsis StudySevere SepsisBlood - Other blood disordersACTRN12607000028404Australia New Zealand Intensive Care Research Centre, a centre of Monash University250
进行中（未招募）
不适用
A study the effects of ARA 290 administered subcutaneously on nerve disease in patients with type 2 diabetesDiabetes type 2: neuropathic symptomsEUCTR2012-005590-32-NLeiden University Medical Center